Achondroplasia Treatment Market

Ongoing clinical studies for growth hormone therapy in patients with rare disease achondroplasia would push the market growth for achondroplasia treatment market

 

Reports and Insights (R&I) has published a new report titled, Achondroplasia Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028

Global Achondroplasia Treatment Market, by Treatment Type (Growth Hormone therapy, surgery), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.

As per the report, the incidence of achondroplasia and the launch of new therapies is the prime factor driving the growth of the achondroplasia treatment market. Achondroplasia is a rare genetic (inherited) bone disorder that occurs in one in 15,000 to 40,000 live births. Achondroplasia is the most common type of dwarfism, in which the child's arms and legs are short in proportion to body length.

Achondroplasia is an autosomal dominant disease. Approximately 80% of achondroplasia cases result from a new mutation in families. In the U.S. approximately 10,000 individuals are estimated to have achondroplasia. The prevalence of achondroplasia in the U.S. ranges from .36 to 0.60 per 10,000 live births. Achondroplasia accounts for 90% of dwarfism or disproportionate short stature. The worldwide prevalence of achondroplasia was found to be 1 in every 25,000–30,000 individuals. That, in turn, translates into around 250,000 affected persons worldwide. The condition affects men and women equally. Studies performed in Texas showed that fathers that >40 years of age had significantly increased rates of de novo achondroplasia among their offspring compared with younger fathers.

Furthermore, Reports and Insights (R&I) Study identifies that, currently, there is no treatment available to prevent or correct achondroplasia, because the majority of cases result from unexpected new mutations. Long term treatment with growth hormone is recommended. Treatment with growth hormone is continued throughout the teen years and early adulthood to ensure adult maturation, such as appropriate gain in muscle or fat. Some patients may require lifelong therapy.

However, treatment with growth hormone does not substantially affect the height of an individual with achondroplasia. In some cases, leg-lengthening surgeries may be considered. Surgeries to correct the spine, or bone problems, as well, as to reduce the pressure inside the brain in cases of hydrocephaly are also recommended. Control of obesity is essential, and obesity can be a significant problem in people with achondroplasia. Some of the well-established brands of growth hormone are Norditropin, Accretropin, Omnitrope, Saizen, Genotropin, Nutropin, Humatrope, etc.

 R&I Study identifies some of the key participating players in the achondroplasia treatment market globally are WITTENSTEIN SE, Novo Nordisk A/S, Cangene Corporation, Novartis AG, Merck KGaA (Emd Serono), Pfizer Inc. Hoffman La Roche (Genentech), Eli Lilly & Co. Ltd., Ipsen Pharma, Ferring Pharmaceuticals Inc., etc. among others.

About Reports and Insights (R&I):

Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Reports and Insights (R&I)

Tel: +1-(281)-619-8646

For Sales Queries: [email protected]

For New Topics and Other Info: [email protected]





This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK